Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma
Luise Fischer, Nora Grieb, Patrick Born, et al.
Leukemia (2024) Vol. 38, Iss. 2, pp. 372-382
Open Access | Times Cited: 20

Showing 20 citing articles:

A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
David M. Cordas dos Santos, Tobias Tix, Roni Shouval, et al.
Nature Medicine (2024) Vol. 30, Iss. 9, pp. 2667-2678
Open Access | Times Cited: 60
Toxicity of CAR T-Cell Therapy for Multiple Myeloma
Aimaz Afrough, Pearl Abraham, Laura Turer, et al.
Acta Haematologica (2024), pp. 1-15
Open Access | Times Cited: 7
Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma
Mateo Mejía Saldarriaga, Darren Pan, Caitlin Unkenholz, et al.
Blood Advances (2024) Vol. 8, Iss. 15, pp. 3859-3869
Open Access | Times Cited: 6
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies
Zhongfei Tao, Zuzana Chyra, Jana Kotulová, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 6
CAR-T cell therapy in the treatment of relapsed or refractory primary central nervous system lymphoma: recent advances and challenges
Shuzhen Xiong, S. Zhang, Ningning Yue, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-13
Closed Access
A wearable device for continuous monitoring of circulating cells at single-cell resolution
Kyuho Jang, Shivam N. Kajale, Baju Joy, et al.
Deleted Journal (2025) Vol. 2, Iss. 1
Open Access
Implications of lymphocyte kinetics after chimeric antigen receptor T cell therapy for multiple myeloma
Sarah Dingli, Paul Rothweiler, Moritz Binder, et al.
Leukemia (2025)
Open Access
Strategies for salvage therapy post CAR-T therapy failure in refractory/relapsed multiple myeloma patients
Chao Min, Xiong Zhong, Yue Cui, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Total body irradiation primes CD19-directed CAR T cells against large B-cell lymphoma
Mohammad Alhomoud, Michelle Foley, Mayumi Sugita, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
The management of multiple myeloma patients accompanied with disseminated intravascular coagulation before receiving LCAR-B38M therapy
Ruijun Dong, Rui Liu, Rui Yang, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS
Katia Mancuso, Marco Talarico, Enrica Manzato, et al.
Cancers (2025) Vol. 17, Iss. 9, pp. 1514-1514
Open Access
Effects on the Physical Functioning of Two Exercise Interventions in Patients with Multiple Myeloma: A Pilot Feasibility Study
Jens Hillengaß, Michaela Hillengaß, Janine M. Joseph, et al.
Cancers (2024) Vol. 16, Iss. 9, pp. 1774-1774
Open Access | Times Cited: 3
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
Maximilian Merz, Danai Dima, Hamza Hashmi, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
Changes in T‐cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T‐cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study
Xiang Zhou, V. Wagner, Lukas Scheller, et al.
British Journal of Haematology (2024) Vol. 205, Iss. 3, pp. 999-1010
Open Access | Times Cited: 2
Chimeric antigen receptor T‐cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice
Céline Gregoire, Beatriz Coutinho de Oliveira, Paolo F. Caimi, et al.
British Journal of Haematology (2024)
Open Access | Times Cited: 2
Directed evolution-based discovery of ligands for in vivo restimulation of CAR-T cells
Tomasz M. Grzywa, Alexandra Neeser, R. Ramasubramanian, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Fast and furious: Changing gears on the road to cure with chimeric antigen receptor T cells in multiple myeloma
Nico Gagelmann, Maximilian Merz
Seminars in Hematology (2024) Vol. 61, Iss. 5, pp. 306-313
Open Access | Times Cited: 1
Reply to Z. Yin et al
Nico Gagelmann, Maximilian Merz
Journal of Clinical Oncology (2024) Vol. 42, Iss. 25, pp. 3064-3064
Closed Access
CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF MULTIPLE MYELOMA
Ugo Testa, Elvira Pelosi, Germana Castelli
Mediterranean Journal of Hematology and Infectious Diseases (2024) Vol. 16, Iss. 1, pp. e2024077-e2024077
Open Access
Modeling CAR Response at the Single-Cell Level Using Conditional Optimal Transport
Alice Driessen, Jannis Born, Rocío Castellanos-Rueda, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Choice of activation protocol impacts the yield and quality of CAR T cell product, particularly with older individuals
Palak Mehta, Gemma S. Trollope, P. Leung, et al.
Clinical & Translational Immunology (2024) Vol. 13, Iss. 12
Open Access
Current progress of CAR-T-cell therapy for patients with multiple myeloma
Takahiro Nakashima, Yuki Kagoya
International Journal of Hematology (2024) Vol. 120, Iss. 1, pp. 15-22
Closed Access
Page 1

Scroll to top